View ValuationAroa Biosurgery 향후 성장Future 기준 점검 4/6Aroa Biosurgery (는) 각각 연간 86.8% 및 13.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 86.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.7% 로 예상됩니다.핵심 정보86.8%이익 성장률86.41%EPS 성장률Biotechs 이익 성장25.2%매출 성장률13.2%향후 자기자본이익률9.65%애널리스트 커버리지Low마지막 업데이트05 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 30Aroa Biosurgery Limited Completes Randomised Controlled Trial for SymphonyAroa Biosurgery Limited announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and Matrix-like Product (CAMP), or skin substitute, designed for the treatment of hard-to-heal wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers. The product combines multiple layers of AROA ECM with high molecular weight hyaluronic acid. The prospective, multi-centre, randomised trial evaluated the safety and performance of Symphony in the treatment of chronic Wagner grade 1 and 2 non-healing diabetic foot ulcers. Patients were randomised to receive either Symphony or standard of care (SOC) dressings on a weekly basis until wound healing or for up to 12 weeks. The study design provided for recruitment of up to 150 patients across multiple sites in the United States. The primary endpoint assessed whether more diabetic foot ulcers healed within the 12-week treatment period with Symphony compared with SOC. Based on the preliminary read-out, the Company believes the trial met its primary endpoint. AROA expects that, once confirmed through final analysis and publication, the results will further support Symphony's clinical efficacy in the management of diabetic foot ulcers. The Company also believes publication of the full study results will help meet the high standard of clinical evidence likely to be required under future reimbursement policies.공시 • Feb 17Aroa Biosurgery Limited to Report Fiscal Year 2026 Results on May 31, 2026Aroa Biosurgery Limited announced that they will report fiscal year 2026 results at 10:00 AM, AUS Eastern Standard Time on May 31, 2026공시 • Oct 09Aroa Biosurgery Limited to Report Q2, 2026 Results on Oct 16, 2025Aroa Biosurgery Limited announced that they will report Q2, 2026 results Pre-Market on Oct 16, 2025공시 • Aug 28Aroa Biosurgery Announces the Findings of the First in Human Study Inviding Its New ENIVO Platform TechnologyAROA announced the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitled Prospective, First-in-Human Clinical Evaluation of a Novel Tissue Apposition Device (ENIVO™?) Following Simple Unilateral Mastectomy, which was published in the well-respected journal, Plastic and Reconstructive Surgery, Global Open. The ENIVO platform is designed for the management of 'dead space,' which is an open cavity created by surgical separation or excision of soft tissue. Dead spaces commonly fill with seroma, which can lead to secondary complications, increase the risk of infection, and lengthen hospital stays for patients. AROA's novel ENIVO system is comprised of a wearable vacuum pump connected to a tube and an Aroa ECM sleeve which is implanted within the patient's body. It delivers suction to the surgical site and allows the tissue surfaces at the surgical site to be held closely together, aiming to eliminate the dead space, remove fluid, and improve the speed and quality of healing. The multi-center study, which involved ten patients who had undergone simple unilateral mastectomy where all tissue from one breast is removed, was conducted in New Zealand and led by Associate Professor Michelle B. Locke, MBChB MD. The ENIVO system was used as an alternative to a surgical drain, which is the current standard of care. The shortcomings of drains are well-known - they can fail due to blockages and often lead to seroma formation. Seromas (a collection of fluid that accumulates in a surgical cavity) are one of the most common complications following mastectomy, with reported incidence rates as high as 22-43%. Seromas are associated with delayed wound healing, increased risk of infection and unsatisfactory aesthetic results. The study monitored the patients for a period of three months postoperatively and found that the ENIVO device performed as designed and all patients healed well, with only one clinically relevant seroma recorded. AROA estimates the market opportunity for ENIVO to be in excess of USD 1B, and is actively pursuing commercialisation, with two out of three of the components already having received US FDA clearance. ENIVO is a device in development and is not currently cleared for use in the tested configuration within the United States.공시 • Jul 22Aroa Biosurgery Limited to Report Q1, 2026 Results on Jul 29, 2025Aroa Biosurgery Limited announced that they will report Q1, 2026 results at 9:00 AM, E. Australia Standard Time on Jul 29, 2025공시 • Jun 27Aroa Biosurgery Limited to Report First Half, 2026 Results on Nov 25, 2025Aroa Biosurgery Limited announced that they will report first half, 2026 results on Nov 25, 2025공시 • Jun 25Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025.공시 • May 02Aroa Biosurgery Hits Evidence Milestone with Real-World Study Validating the Efficacy of Endoform in Treating Venous Leg UlcersAroa Biosurgery announced a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology. AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing. VLUs are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only 40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur. The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025. The study compared 470 VLUs that had been treated with Endoform Natural to 360 VLUs that had been treatment with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that ' real-world' use of both products could be compared. The study found that VLUs treated with Endoform Natural healed up to 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment. The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural. This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituting collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural. Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72. Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comprehensive effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022;19:7):741-753.공시 • Apr 22Aroa Biosurgery Limited to Report Q4, 2025 Results on Apr 29, 2025Aroa Biosurgery Limited announced that they will report Q4, 2025 results Pre-Market on Apr 29, 2025이익 및 매출 성장 예측OTCPK:AROA.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (NZD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/2029153N/AN/AN/A13/31/202813714161833/31/20271198101333/31/20261044101139/30/202590-236N/A6/30/202588-3-22N/A3/31/202585-4-6-3N/A12/31/202481-6-9-4N/A9/30/202476-8-11-5N/A6/30/202473-9-13-6N/A3/31/202469-11-14-7N/A12/31/202367-9-15-7N/A9/30/202366-8-15-6N/A6/30/202365-4-13-5N/A3/31/2023630-11-4N/A12/31/202257-1-13-7N/A9/30/202251-2-15-10N/A6/30/202245-5-16-11N/A3/31/202240-8-16-12N/A12/31/202135-10-14-10N/A9/30/202131-11-11-8N/A6/30/202127-15-9-6N/A3/31/202122-19-7-5N/A12/31/202022-19-6-5N/A9/30/202021-19-6-4N/A6/30/202023-12-3-1N/A3/31/202025-602N/A3/31/2019241N/A0N/A3/31/201811-1N/A-3N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: AROA.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: AROA.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: AROA.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: AROA.F 의 수익(연간 13.2%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: AROA.F 의 수익(연간 13.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: AROA.F의 자본 수익률은 3년 후 9.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 18:03종가2026/05/20 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aroa Biosurgery Limited는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관John HesterBell PotterElyse ShapiroCanaccord GenuityShane StoreyCanaccord Genuity2명의 분석가 더 보기
공시 • Mar 30Aroa Biosurgery Limited Completes Randomised Controlled Trial for SymphonyAroa Biosurgery Limited announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and Matrix-like Product (CAMP), or skin substitute, designed for the treatment of hard-to-heal wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers. The product combines multiple layers of AROA ECM with high molecular weight hyaluronic acid. The prospective, multi-centre, randomised trial evaluated the safety and performance of Symphony in the treatment of chronic Wagner grade 1 and 2 non-healing diabetic foot ulcers. Patients were randomised to receive either Symphony or standard of care (SOC) dressings on a weekly basis until wound healing or for up to 12 weeks. The study design provided for recruitment of up to 150 patients across multiple sites in the United States. The primary endpoint assessed whether more diabetic foot ulcers healed within the 12-week treatment period with Symphony compared with SOC. Based on the preliminary read-out, the Company believes the trial met its primary endpoint. AROA expects that, once confirmed through final analysis and publication, the results will further support Symphony's clinical efficacy in the management of diabetic foot ulcers. The Company also believes publication of the full study results will help meet the high standard of clinical evidence likely to be required under future reimbursement policies.
공시 • Feb 17Aroa Biosurgery Limited to Report Fiscal Year 2026 Results on May 31, 2026Aroa Biosurgery Limited announced that they will report fiscal year 2026 results at 10:00 AM, AUS Eastern Standard Time on May 31, 2026
공시 • Oct 09Aroa Biosurgery Limited to Report Q2, 2026 Results on Oct 16, 2025Aroa Biosurgery Limited announced that they will report Q2, 2026 results Pre-Market on Oct 16, 2025
공시 • Aug 28Aroa Biosurgery Announces the Findings of the First in Human Study Inviding Its New ENIVO Platform TechnologyAROA announced the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitled Prospective, First-in-Human Clinical Evaluation of a Novel Tissue Apposition Device (ENIVO™?) Following Simple Unilateral Mastectomy, which was published in the well-respected journal, Plastic and Reconstructive Surgery, Global Open. The ENIVO platform is designed for the management of 'dead space,' which is an open cavity created by surgical separation or excision of soft tissue. Dead spaces commonly fill with seroma, which can lead to secondary complications, increase the risk of infection, and lengthen hospital stays for patients. AROA's novel ENIVO system is comprised of a wearable vacuum pump connected to a tube and an Aroa ECM sleeve which is implanted within the patient's body. It delivers suction to the surgical site and allows the tissue surfaces at the surgical site to be held closely together, aiming to eliminate the dead space, remove fluid, and improve the speed and quality of healing. The multi-center study, which involved ten patients who had undergone simple unilateral mastectomy where all tissue from one breast is removed, was conducted in New Zealand and led by Associate Professor Michelle B. Locke, MBChB MD. The ENIVO system was used as an alternative to a surgical drain, which is the current standard of care. The shortcomings of drains are well-known - they can fail due to blockages and often lead to seroma formation. Seromas (a collection of fluid that accumulates in a surgical cavity) are one of the most common complications following mastectomy, with reported incidence rates as high as 22-43%. Seromas are associated with delayed wound healing, increased risk of infection and unsatisfactory aesthetic results. The study monitored the patients for a period of three months postoperatively and found that the ENIVO device performed as designed and all patients healed well, with only one clinically relevant seroma recorded. AROA estimates the market opportunity for ENIVO to be in excess of USD 1B, and is actively pursuing commercialisation, with two out of three of the components already having received US FDA clearance. ENIVO is a device in development and is not currently cleared for use in the tested configuration within the United States.
공시 • Jul 22Aroa Biosurgery Limited to Report Q1, 2026 Results on Jul 29, 2025Aroa Biosurgery Limited announced that they will report Q1, 2026 results at 9:00 AM, E. Australia Standard Time on Jul 29, 2025
공시 • Jun 27Aroa Biosurgery Limited to Report First Half, 2026 Results on Nov 25, 2025Aroa Biosurgery Limited announced that they will report first half, 2026 results on Nov 25, 2025
공시 • Jun 25Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025.
공시 • May 02Aroa Biosurgery Hits Evidence Milestone with Real-World Study Validating the Efficacy of Endoform in Treating Venous Leg UlcersAroa Biosurgery announced a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology. AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing. VLUs are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only 40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur. The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025. The study compared 470 VLUs that had been treated with Endoform Natural to 360 VLUs that had been treatment with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that ' real-world' use of both products could be compared. The study found that VLUs treated with Endoform Natural healed up to 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment. The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural. This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituting collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural. Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72. Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comprehensive effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022;19:7):741-753.
공시 • Apr 22Aroa Biosurgery Limited to Report Q4, 2025 Results on Apr 29, 2025Aroa Biosurgery Limited announced that they will report Q4, 2025 results Pre-Market on Apr 29, 2025